P Baas

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. doi request reprint Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer
    Paul Baas
    Department of Thoracic Oncology, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
    J Thorac Oncol 3:745-50. 2008
  2. ncbi request reprint Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma
    Eelco de Bree
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Chest 121:480-7. 2002
  3. ncbi request reprint Thalidomide in patients with malignant pleural mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 48:291-6. 2005
  4. ncbi request reprint Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid
    Paul Baas
    Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Chest 129:718-24. 2006
  5. ncbi request reprint The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)
    P Baas
    The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Eur J Cancer 39:353-7. 2003
  6. ncbi request reprint Predictive and prognostic factors in malignant pleural mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Oncol 15:127-30. 2003
  7. pmc Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study
    P Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 94:625-30. 2006
  8. ncbi request reprint Optimising survival in malignant mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 57:S24-9. 2007
  9. ncbi request reprint Inductive and adjuvant treatment strategies for localized nonsmall cell lung cancer in operable and inoperable patients
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Oncol 14:180-4. 2002
  10. ncbi request reprint Chemotherapy for malignant mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 49:S61-4. 2005

Detail Information

Publications69

  1. doi request reprint Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer
    Paul Baas
    Department of Thoracic Oncology, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
    J Thorac Oncol 3:745-50. 2008
    ..A phase I/II study was performed to assess the efficacy and toxicity of a new oral taxane in patients with recurrent, advanced Non-small Cell Lung Cancer...
  2. ncbi request reprint Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma
    Eelco de Bree
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Chest 121:480-7. 2002
    ..We investigated the feasibility and safety of this multimodality treatment in the thoracic cavity...
  3. ncbi request reprint Thalidomide in patients with malignant pleural mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 48:291-6. 2005
    ..The purpose of this study was to describe the experience with the anti-angiogenic agent thalidomide in the treatment of patients with a malignant pleural mesothelioma (MPM)...
  4. ncbi request reprint Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid
    Paul Baas
    Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Chest 129:718-24. 2006
    ..Fluorescence diagnosis (FD) with 5-aminolaevulinic acid (5-ALA) has been used in the diagnostic workup for various malignancies. The impact of 5-ALA-mediated FD on diagnosis and staging during video-assisted thoracoscopy was examined...
  5. ncbi request reprint The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)
    P Baas
    The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Eur J Cancer 39:353-7. 2003
    ..We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted...
  6. ncbi request reprint Predictive and prognostic factors in malignant pleural mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Oncol 15:127-30. 2003
    ..In the following article, the recent knowledge about these factors is presented in order to determine the patients who may benefit most from current experimental therapies...
  7. pmc Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study
    P Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 94:625-30. 2006
    ..This study indicates that combination chemotherapy with concurrent involved-field radiation therapy is an effective treatment for LS-SCLC. Despite PCI, the brain remained the most important site of recurrence...
  8. ncbi request reprint Optimising survival in malignant mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 57:S24-9. 2007
    ..Standard treatment is the combination of cisplatin and pemetrexed based on phase III-study evidence, and therapy should be initiated as early as possible...
  9. ncbi request reprint Inductive and adjuvant treatment strategies for localized nonsmall cell lung cancer in operable and inoperable patients
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Oncol 14:180-4. 2002
    ..Implementation of these agents is expected to have great impact on the survival in patients with nonsmall cell lung cancer...
  10. ncbi request reprint Chemotherapy for malignant mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 49:S61-4. 2005
  11. ncbi request reprint [Problematic cases of mesothelioma reported to the Dutch Institute for Asbestos Victims: evaluation by the Mesothelioma Working Group of the Netherlands Association of Pulmonologists and Specialists in Tuberculosis]
    P Baas
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Thorax oncologie, Plesmanlaan 121, 1066 CX Amsterdam
    Ned Tijdschr Geneeskd 149:759-63. 2005
    ..To analyse the assessments of problematic cases reported to the Dutch Institute for Asbestos Victims (IAS) by the Mesothelioma Working Party of the Netherlands Association of Pulmonologists and Specialists in Tuberculosis (NVALT)...
  12. ncbi request reprint [Development in the treatment of malignant mesothelioma]
    P Bass
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Thorax oncologie, Amsterdam
    Ned Tijdschr Geneeskd 149:747-53. 2005
    ..The current studies focus on the use of chemotherapy and biological agents as part of a more complex treatment schedule...
  13. ncbi request reprint Occupational asbestos exposure: how to deal with suspected mesothelioma cases--the Dutch approach
    P Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Oncol 17:848-52. 2006
    ..The process of data handling and final outcome for these patients is discussed and compared with the situation in other European countries...
  14. doi request reprint Chemoradiation therapy in nonsmall cell lung cancer
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Oncol 23:140-9. 2011
    ..In this review we present a short history of the developments in this field with an update of all new developments. We address the questions how to optimally combine chemotherapy, targeted agents and radiation therapy...
  15. ncbi request reprint The prognostic significance of a previous malignancy in operable non-small cell lung cancer
    M J Koppe
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 166, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 32:47-53. 2001
    ..NSCLC diagnosed during the follow-up of a previous malignancy, and deemed operable, therefore, warrants the same diagnostic and therapeutic approach as NSCLC as first malignancy...
  16. doi request reprint Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
    M Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Lung Cancer 74:310-7. 2011
    ..The aim of this study was to assess the predictive value of tumor expression of nine genes on clinical outcome in patients with advanced NSCLC receiving platinum-gemcitabine chemotherapy...
  17. doi request reprint Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
    M Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 69:25-33. 2012
    ..This study quantified the impact of drug pathway-associated genetic variants on the pharmacokinetics (PK) of gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)...
  18. ncbi request reprint Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols
    H Schouwink
    Division of Experimental Therapy (H6, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Photochem Photobiol 73:410-7. 2001
    ..Nicotinamide injection and carbogen breathing significantly increased tumor oxygenation and increased the tumor response for PDT schedules with illumination at 24 h after photosensitizer injection...
  19. pmc Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies
    P Baas
    The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam
    Br J Cancer 76:819-26. 1997
    ..This combination of light delivery and dosimetry is well suited for adjuvant treatment with PDT in malignant pleural tumours...
  20. ncbi request reprint Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma
    S van Ruth
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Surg Oncol 10:176-82. 2003
    ..Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy is used to kill residual tumor cells on the surface of the thoracic cavity while having limited systemic side effects...
  21. ncbi request reprint Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer
    C M F Kruijtzer
    Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 20:4508-16. 2002
    ..A phase II study was performed to assess the efficacy and toxicity of oral cyclosporine (CsA) plus paclitaxel in advanced non-small-cell lung cancer (NSCLC)...
  22. ncbi request reprint Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results
    H Schouwink
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Chest 120:1167-74. 2001
    ..The considerable toxicity associated with the procedure, however, precludes its recommendation for widespread use. Stricter patient selection and improvements of the IPDT technique may reduce the toxicity...
  23. ncbi request reprint Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers
    J M Klaase
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Amsterdam, The Netherlands
    Photochem Photobiol 71:351-4. 2000
    ..From this study in patients with MPM treated with pleuropneumonectomy and IPDT it can be concluded that measurement of cTnI and cTnT for the detection of myocardial damage is more suitable than measurement of the classical markers...
  24. ncbi request reprint Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients
    A Haringhuizen
    Departments of Thoracic Oncology and Biometrics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Ann Oncol 15:786-92. 2004
    ..We describe 16 months' single-institution experience with gefitinib ("Iressa", ZD1839) used as "ultimum refugium" for pretreated non-small-cell lung cancer (NSCLC) patients...
  25. ncbi request reprint Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study
    P Baas
    Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Dermatol 145:75-8. 2001
    ..Photodynamic therapy (PDT) is a convenient and effective method of treating small superficial tumours. New second-generation photosensitizers offer some advantages over first-generation sensitizers such as haematoporphyrin derivatives...
  26. ncbi request reprint EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
    N Van Zandwijk
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Oncol 18:99-103. 2007
    ..Exon 19 deletions that are associated with the best responses might be used for first-line treatment selection, while KRAS mutations could play a role in excluding patients from treatment with TKIs...
  27. doi request reprint Surgical treatment in the management of malignant pleural mesothelioma: a single institution's experience
    J W van Sandick
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Ann Surg Oncol 15:1757-64. 2008
    ..The most effective combination is unknown. In our institute we have retrospectively analyzed the results of two combined modality regimens containing surgery...
  28. pmc Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study
    P Baas
    Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Br J Cancer 73:945-51. 1996
    ..3) Restoration of skin after PDT in previously treated tumour areas (chemotherapy, radiation therapy and surgery) is very low...
  29. pmc Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
    M Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, and Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, The Netherlands
    Br J Clin Pharmacol 62:71-80. 2006
    ..To characterize determinants of the elimination of methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) in patients receiving high-dose MTX therapy (HDMTX)...
  30. ncbi request reprint Caelyx in malignant mesothelioma: a phase II EORTC study
    P Baas
    TheNetherlands Cancer Institute, Amsterdam
    Ann Oncol 11:697-700. 2000
    ..In a phase II study, the efficacy and toxicity of Caelyx was tested in previously untreated patients with malignant pleural mesothelioma...
  31. ncbi request reprint Necrotizing pneumonitis caused by postoperative pulmonary torsion
    Simon Hennink
    Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Interact Cardiovasc Thorac Surg 7:144-5. 2008
    ..Detorsion, instead of resection, may lead to fatal complications. Although infrequent, one should be aware of lobar torsion and the necessity for immediate re-intervention...
  32. ncbi request reprint Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy
    Jose S A Belderbos
    Department of Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 66:126-34. 2006
    ..The impact of tumor volume and delivered dose on failure-free interval (FFI) and overall survival (OS) were also studied...
  33. ncbi request reprint Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial
    Alexandre Mathy
    Biometrics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 50:83-6. 2005
    ..Side effects of the medication were mild and included edema, nausea, constipation and diarrhea. We conclude that further investigation with monotherapy imatinib in mesothelioma is not warranted...
  34. ncbi request reprint Surgical treatment of malignant pleural mesothelioma: a review
    Serge van Ruth
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Chest 123:551-61. 2003
    ..In recent years, the emphasis has been on surgery combined with adjuvant therapies. In this article, the present state of surgical management of MPM will be reviewed...
  35. doi request reprint Evaluation of (18)F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment
    Tjeerd S Aukema
    Department of Nuclear Medicine, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Thorac Oncol 4:1226-30. 2009
    ....
  36. ncbi request reprint Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer
    Katrien De Jaeger
    Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 55:1331-40. 2003
    ..To study changes of pulmonary function tests (PFTs) after radiotherapy (RT) of non-small-cell lung cancer (NSCLC) in relation to radiation dose, tumor regression, and changes in lung perfusion...
  37. ncbi request reprint Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC
    Nico van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Suppl Tumori 1:S37-8. 2002
  38. ncbi request reprint Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin
    Eelco de Bree
    Department of Surgical Oncology, Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Surg Oncol 14:3019-26. 2007
    ..In the present study, early cardiotoxicity of this treatment modality was prospectively analyzed...
  39. ncbi request reprint Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer
    Milly E de Jonge
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 10:2237-44. 2004
    ..The paclitaxel dose of a subsequent course was increased to the lowest dose for which the predicted time period during which the paclitaxel plasma concentration exceeds 0.1 micromol/liter was >15 h...
  40. ncbi request reprint Relationship between cisplatin administration and the development of ototoxicity
    Jeany M Rademaker-Lakhai
    Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital and Department of Audiology, Academic Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 24:918-24. 2006
    ..To determine the auditory toxicity associated with dose- and schedule- intensive cisplatin/gemcitabine chemotherapy in non-small-cell lung carcinoma patients...
  41. ncbi request reprint The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma
    J Hugo Schouwink
    Department of Thoracic Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Thorac Surg 75:1715-8; discussion 1718-9. 2003
    ..In this study cervical mediastinoscopy (CM) is compared with computer tomography (CT) scanning for its diagnostic accuracy in assessing mediastinal lymph nodes during preoperative workup...
  42. ncbi request reprint Long term survival of thoracoscopic metastasectomy vs metastasectomy by thoracotomy in patients with a solitary pulmonary lesion
    E L A R Mutsaerts
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Amsterdam, The Netherlands
    Eur J Surg Oncol 28:864-8. 2002
    ..The aim of this study was to compare long term survival after resection of solitary pulmonary metastasis on CT scan performed by either thoracoscopy or through a standard thoracotomy...
  43. doi request reprint An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival
    C M Korse
    Department of Clinical Chemistry, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Oncol 22:2625-30. 2011
    ..In well-differentiated neuroendocrine tumours (WDNETs), this study investigates the association between proGRP and tumour characteristics and the prognostic value of proGRP levels compared with chromogranin A (CgA) levels...
  44. ncbi request reprint Radiation pneumonitis imaged with indium-111-pentetreotide
    R A Valdes Olmos
    Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Nucl Med 37:584-8. 1996
    ..Early recognition of radiation pneumonitis enables adequate treatment with a reasonable chance to prevent late sequelae. The feasibility of 111In-pentetreotide in detecting this condition was explored in this study...
  45. ncbi request reprint [Chronic indwelling pleural catheter for malignant pleural effusion in 25 patients]
    J A Burgers
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Thoracale Oncologie, Plesmanlaan 121, Amsterdam
    Ned Tijdschr Geneeskd 150:1618-23. 2006
    ..To describe the experience with an indwelling pleural catheter in patients with pleuritis carcinomatosa...
  46. ncbi request reprint [Bronchoscopy: new diagnostic and therapeutic technology, new indications]
    J A Burgers
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Thoracale Oncologie, Plesmanlaan 121, 1066 CX Amsterdam
    Ned Tijdschr Geneeskd 148:1280-5. 2004
    ..Electrocauterization and laser dissection are regularly used to remove intrabronchial tumour depositions. Airway stenting is indicated if there are stenoses caused by compression from abnormalities located externally to the airways...
  47. ncbi request reprint First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy
    Jose S A Belderbos
    Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX The, Amsterdam, Netherlands
    Radiother Oncol 66:119-26. 2003
    ..To evaluate the feasibility of dose escalation in non-small cell lung cancer (NSCLC) using three-dimensional conformal radiation therapy...
  48. ncbi request reprint Optimizing radiation treatment plans for lung cancer using lung perfusion information
    Yvette Seppenwoolde
    Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Radiother Oncol 63:165-77. 2002
    ..To study the impact of incorporation of lung perfusion information in the optimization of radical radiotherapy (RT) treatment plans for patients with medically inoperable non-small cell lung cancer (NSCLC)...
  49. ncbi request reprint The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men
    Martijn Triesscheijn
    Division of Experimental Therapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 60:113-22. 2007
    ..Our aim was to determine the pharmacokinetics of mTHPC in detail, and to investigate whether the pharmacokinetic behavior of the drug is affected by binding of mTHPC to lipoproteins in vivo...
  50. ncbi request reprint Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Semin Oncol 29:62-9. 2002
    ..Other types of response evaluation and guidelines for patient selection are warranted to properly compare chemotherapeutic treatments...
  51. ncbi request reprint Non-invasive diagnosis of pleural malignancies: the role of tumour markers
    Michel M Van Den Heuvel
    Department of Thoracic Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 59:350-4. 2008
    ..We have assessed three different serum markers and report our findings in a series of patients with different thoracic malignancies and a group of healthy controls...
  52. doi request reprint Malignant mesothelioma after radiation treatment for Hodgkin lymphoma
    Marie L De Bruin
    Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam
    Blood 113:3679-81. 2009
    ..The evidence for radiotherapy as cause for mesothelioma independent of exposure to asbestos is expanding, and the diagnosis of mesothelioma should be kept in mind whenever related symptoms arise in patients who had previous irradiation...
  53. ncbi request reprint Doppler optical coherence tomography to monitor the effect of photodynamic therapy on tissue morphology and perfusion
    Maurice C G Aalders
    University of Amsterdam, Academic Medical Center, Laser Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    J Biomed Opt 11:044011. 2006
    ..The concept of using noninvasive OCT measurements for monitoring early, treatment-related changes in morphology and perfusion may have applications in evaluating effects of anti-angiogenic or antivascular (cancer) therapy...
  54. ncbi request reprint Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer
    Jeany M Rademaker-Lakhai
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Anticancer Drugs 16:1029-36. 2005
    ..We conclude that the combination of cisplatin at a dose intensity of 51 mg/m/week followed by gemcitabine (1500 mg/m) on the same day is clinically feasible in NSCLC patients when given as a 2-weekly cycle...
  55. ncbi request reprint Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response
    Martijn Triesscheijn
    Division of Experimental Therapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Photochem Photobiol 81:1161-7. 2005
    ..These data show that optimal responses to mTHPC-mediated PDT were primarily dependent on the early vascular response, and that plasma drug levels at the time of illumination could predict this relationship...
  56. ncbi request reprint Photodynamic therapy in oncology
    Martijn Triesscheijn
    Division of Experimental Therapy H6, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Oncologist 11:1034-44. 2006
    ..Here, we show the developmental steps PDT underwent and summarize the current clinical applications. The data show that, when properly used, PDT is an effective alternative treatment option in oncology...
  57. ncbi request reprint Optimizing meso-tetra-hydroxyphenyl-chlorin-mediated photodynamic therapy for basal cell carcinoma
    Martijn Triesscheijn
    Division of Experimental Therapy H6, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    Photochem Photobiol 82:1686-90. 2006
    ..We optimized mTHPC-mediated PDT for patients suffering from multiple BCC by determining the most effective drug-light interval and showed that this treatment offers significant advantages over surgical resection...
  58. doi request reprint Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program
    Armando Santoro
    Istituto Clinico Humanitas, Rozzano, Italy
    J Thorac Oncol 3:756-63. 2008
    ..This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaïve patients receiving pemetrexed plus platinum under the EAP...
  59. doi request reprint Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer
    Heather Wakelee
    Department of Medicine, Division of Oncology, Stanford Cancer Center, Stanford, California 94305 5826, USA
    Clin Lung Cancer 9:9-15. 2008
    ..Ongoing trials within the cooperative groups continue to drive steady improvement in the treatment of lung cancer and offer great promise for the future...
  60. doi request reprint Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
    Corey J Langer
    Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Clin Lung Cancer 9:85-91. 2008
    ..These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting...
  61. ncbi request reprint Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer
    Mirjam Crul
    Netherlands Cancer Institute, Departments of Medical Oncology, The Netherlands
    Clin Cancer Res 9:3526-33. 2003
    ..To establish the maximum dose intensity of cisplatin plus gemcitabine on a weekly or two-weekly schedule in patients with advanced non-small cell lung cancer (NSCLC)...
  62. ncbi request reprint Foscan-mediated photodynamic therapy and operation for malignant pleural mesothelioma
    Hugo Schouwink
    Ann Thorac Surg 78:388; author reply 388-9. 2004
  63. ncbi request reprint Innovative therapies: photodynamic therapy
    Evelio Rodriguez
    Division of Thoracic Surgery, Thomas Jefferson University, 1025 Walnut Street, Suite 605, Philadelphia, PA 19107, USA
    Thorac Surg Clin 14:557-66. 2004
    ..One attractive aspect of this adjuvant treatment is that PDT, as opposed to some of the other adjuvant treatments combined with surgery, may offer the option of effecting adequate tumor debulking with a pulmonary-sparing procedure...
  64. ncbi request reprint Malignant pleural mesothelioma: overview of the North American and European experience
    Jasleen Kukreja
    Division of Thoracic Surgery, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Thorac Surg Clin 14:435-45. 2004
    ....
  65. ncbi request reprint Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers
    Frederik Jan van Schooten
    Department of Health Risk Analysis and Toxicology, Maastricht University, The Netherlands
    Cancer Epidemiol Biomarkers Prev 11:167-75. 2002
    ..1) but not on BAL fluid antioxidant scavenging capacity. We conclude that NAC has the potential to impact upon tobacco smoke carcinogenicity in humans because it can modulate certain cancer-associated biomarkers in specific organs...
  66. ncbi request reprint CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone
    Remco M van den Berg
    Department of Pulmonology, VU University Medical Center, Boelelaan 1117, 1081HV Amsterdam, The Netherlands
    Lung Cancer 60:57-61. 2008
    ..We performed a secondary analysis of CT data of subjects at risk of lung cancer enrolled in a chemoprevention trial of fluticasone...
  67. ncbi request reprint Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient
    Andrea Zimmermann
    Research Division of Gynaecology, Department of Gynaecology and Obstetrics, University Hospital Zurich, 8091 Zurich, Switzerland
    Cancer Chemother Pharmacol 51:147-54. 2003
    ..The healing process was delayed by 2 months compared to PDT alone. It is therefore important to find optimal conditions under which PDT and chemotherapy combinations do not fall outside the therapeutic window...
  68. ncbi request reprint Comparative sensitivity of microvascular endothelial cells, fibroblasts and tumor cells after in vitro photodynamic therapy with meso-tetra-hydroxyphenyl-chlorin
    Martijn Triesscheijn
    Division of Experimental Therapy H6, The Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, 1066 CXAmsterdam, The Netherlands
    Photochem Photobiol 80:236-41. 2004
    ....
  69. ncbi request reprint The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium
    Remco M van den Berg
    Department of Pulmonology, VU Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Am J Respir Crit Care Med 175:1061-5. 2007
    ..Bronchial epithelium exposed to cigarette smoke undergoes a series of histologic changes that may ultimately lead to invasive cancer. Inhaled corticosteroids reduce the number of lung tumors developing in rats exposed to cigarette smoke...